Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

'Pharmed' Red Blood Cells as Novel Therapeutics for Life Threatening-Infections

FY 2013-14

Summary
Life threatening infections, including severe malaria and sepsis, are leading causes of mortality around the world. Our current treatments are not enough and, in order, to save lives we need to develop new therapeutics. During these severe infections, the lining of your blood vessels becomes activated and dysfunctional leading to multi-organ failure. The endothelial lining of those vessels interacts extensively with red blood cells which suggests that the red blood cell is an ideal delivery system for new therapeutics. This proposal aims to take advantage of this interaction and modify pharmaceutically engineered red blood cells to deliver increased nitric oxide activity. There are several advantages to using these 'Pharmed' red blood cells: they will be free of blood borne diseases, can be used for people with any blood type, and do not have the potential to cause cancer. Increased ability to deliver nitric oxide is important for these cells because it has been shown that nitric oxide is decreased during severe infections, and is able to stabilize the endothelial lining. Severe malaria will be used as a proof of concept for severe infections. Experiments will be used to 1)Determine the effect of these modified red blood cells on cultured cells from your vessel lining and on the red blood cells containing the malaria parasite; 2) Investigate the effect of these modified red blood cells in a mouse model of severe malaria. The modified red blood cells are primarily targeting the host response, and not the pathogen, therefore, these cells have the potential to be used against other infectious diseases, independent of the organism causing the disease.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
299935
Name
Elphinstone Robyn
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
'Pharmed' Red Blood Cells as Novel Therapeutics for Life Threatening-Infections
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Endothelial Dysfunction; Experimental Mouse Models; Host Response To Infection; Life Threatening Infections; Modified Red Blood Cells; Novel Therapeutics; Severe Malaria
Abstract
Life threatening infections, including severe malaria and sepsis, are leading causes of mortality around the world. Our current treatments are not enough and, in order, to save lives we need to develop new therapeutics. During these severe infections, the lining of your blood vessels becomes activated and dysfunctional leading to multi-organ failure. The endothelial lining of those vessels interacts extensively with red blood cells which suggests that the red blood cell is an ideal delivery system for new therapeutics. This proposal aims to take advantage of this interaction and modify pharmaceutically engineered red blood cells to deliver increased nitric oxide activity. There are several advantages to using these 'Pharmed' red blood cells: they will be free of blood borne diseases, can be used for people with any blood type, and do not have the potential to cause cancer. Increased ability to deliver nitric oxide is important for these cells because it has been shown that nitric oxide is decreased during severe infections, and is able to stabilize the endothelial lining. Severe malaria will be used as a proof of concept for severe infections. Experiments will be used to 1)Determine the effect of these modified red blood cells on cultured cells from your vessel lining and on the red blood cells containing the malaria parasite; 2) Investigate the effect of these modified red blood cells in a mouse model of severe malaria. The modified red blood cells are primarily targeting the host response, and not the pathogen, therefore, these cells have the potential to be used against other infectious diseases, independent of the organism causing the disease.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Elphinstone, Robyn
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2013-14) | Canada Spends